Colonial River Wealth Management LLC Invests $86,000 in Exscientia plc (NASDAQ:EXAI)

Colonial River Wealth Management LLC bought a new stake in Exscientia plc (NASDAQ:EXAIFree Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,415 shares of the company’s stock, valued at approximately $86,000.

Several other hedge funds have also bought and sold shares of EXAI. Softbank Group CORP. acquired a new stake in Exscientia in the 1st quarter valued at about $30,114,000. Point72 Asset Management L.P. acquired a new stake in Exscientia during the fourth quarter worth approximately $4,280,000. Platinum Investment Management Ltd. lifted its position in Exscientia by 10.2% during the third quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company’s stock worth $19,866,000 after acquiring an additional 405,426 shares during the last quarter. Laurion Capital Management LP lifted its position in Exscientia by 10.8% during the fourth quarter. Laurion Capital Management LP now owns 2,363,363 shares of the company’s stock worth $12,597,000 after acquiring an additional 231,209 shares during the last quarter. Finally, Banque Pictet & Cie SA acquired a new stake in Exscientia during the third quarter worth approximately $1,040,000. 41.58% of the stock is currently owned by institutional investors and hedge funds.

Exscientia Price Performance

NASDAQ:EXAI opened at $5.21 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.22 and a quick ratio of 6.22. The firm has a 50-day moving average of $6.17 and a 200-day moving average of $5.87. Exscientia plc has a one year low of $4.17 and a one year high of $9.12.

Wall Street Analyst Weigh In

Separately, Bank of America cut shares of Exscientia from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $11.00 to $9.00 in a research note on Friday, January 5th.

View Our Latest Research Report on EXAI

Exscientia Company Profile

(Free Report)

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.

Recommended Stories

Institutional Ownership by Quarter for Exscientia (NASDAQ:EXAI)

Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.